Bristol Myers Squibb 2023 ESG report

At BMS, our vision to transform patients’ lives through science extends to all patients. That is why we have a long-standing commitment to promote health equity and help people in underserved communities access the care and medicines they need.

At BMS, we understand that the future of our company, employees, communities, and the planet are inextricably linked. Our passion for making an impact extends beyond the discovery, development and delivery of innovative medicines that help patients prevail over serious diseases.

BMS today announced validation for its near-term and net-zero science-based targets from the Science Based Targets initiative (SBTi), as part of a mid-year update on its environmental initiatives, highlighting progress in reducing emissions across its operations and supply chain.

BMS has earned a top score of 100 on the 2024 Disability Equality Index®, naming BMS a Best Place to Work for Disability Inclusion in the U.S., U.K. and Brazil. BMS has earned this score for the sixth consecutive year in the U.S. and for the first time in the U.K. and Brazil.

Bristol Myers Squibb published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company’s meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts.